Phio Pharmaceuticals(US:PHIO) Newsfile·2025-11-13 21:15Core Insights - Phio Pharmaceuticals reported positive clinical trial results for its lead compound PH-762, achieving 100% tumor clearance in one patient and over 90% clearance in another patient in the fifth cohort of its Phase 1b trial [1][2][3] - The company secured approximately $12.1 million in net proceeds from warrant inducement financing, extending its cash runway into the first half of 2027 [1][9] - Financial results for Q3 2025 showed a net loss of $2.4 million, an increase from $1.5 million in Q3 2024, primarily due to higher research and development expenses [1][13] Clinical Trial Progress - The ongoing Phase 1b trial is evaluating the safety and tolerability of PH-762 in patients with various stages of cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma [2][15] - As of now, 18 patients have completed treatment across five cohorts, with cumulative results indicating six complete responses and two near-complete responses among patients with cutaneous squamous cell carcinoma [3][4] Financial Overview - As of September 30, 2025, the company had cash and cash equivalents of approximately $10.7 million, up from $5.4 million at the end of 2024, with an estimated total of $21.3 million post-financing [10][20] - Research and development expenses for Q3 2025 were $1.2 million, compared to $0.6 million in the same period of 2024, driven by increased clinical trial costs [11] - General and administrative expenses rose to $1.3 million in Q3 2025 from $0.9 million in Q3 2024, attributed to higher professional fees and employee stock compensation [12] Business Developments - The company entered into a drug substance development services agreement with a U.S. manufacturer for the cGMP production of clinical supplies for PH-762 in July 2025 [5] - Phio has actively engaged in scientific and investor presentations to showcase its INTASYL technology and clinical trial results [7]